1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: US Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. US Clinical Trials Market, by Phase
8.1.1 Phase I
8.1.1.1. Market Revenue and Forecast
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast
8.1.3. Phase III
8.1.3.1. Market Revenue and Forecast
8.1.4. Phase IV
8.1.4.1. Market Revenue and Forecast
9.1. US Clinical Trials Market, by Study Design
9.1.1. Interventional
9.1.1.1. Market Revenue and Forecast
9.1.2. Observational
9.1.2.1. Market Revenue and Forecast
10.1. US Clinical Trials Market, by Indication
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast
10.1.2. Autoimmune
10.1.2.1. Market Revenue and Forecast
10.1.3. Pain Management
10.1.3.1. Market Revenue and Forecast
10.1.4. CNS Conditions
10.1.4.1. Market Revenue and Forecast
10.1.5. Obesity
10.1.5.1. Market Revenue and Forecast (2022-2032)
10.1.6. Cardiovascular
10.1.6.1. Market Revenue and Forecast
10.1.7. Diabetes
10.1.7.1. Market Revenue and Forecast
11.1. U.S.
11.1.1. Market Revenue and Forecast, by Phase
11.1.2. Market Revenue and Forecast, by Study Design
11.1.3. Market Revenue and Forecast, by Indication
12.1. Parexel International Corp.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Charles River Laboratory
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. PRA Health Sciences
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Wuxi AppTec
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Eli Lilly and Company
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Novo Nordisk A/S
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Clinipace
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Omnicare
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Kendle
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Chiltern
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
